1/
Excellent results for phase 3 placebo-controlled RCT in 🇺🇸 among mild-to-moderate #COVID_19 patients at high risk of clinical deterioration.
Cocktail of 700mg of #bamlanivimab & 1,400mg of #etesevimab reduced risk of hospitalizations & death by 87%.
Excellent results for phase 3 placebo-controlled RCT in 🇺🇸 among mild-to-moderate #COVID_19 patients at high risk of clinical deterioration.
Cocktail of 700mg of #bamlanivimab & 1,400mg of #etesevimab reduced risk of hospitalizations & death by 87%.
https://twitter.com/LillyPad/status/1369620519830585350
2/
This press release needs to be taken with grain of salt. Among other limitations, it says nothing about different variants of concern.
This press release needs to be taken with grain of salt. Among other limitations, it says nothing about different variants of concern.
3/
Concern now is that bamlanivimab is quite accessible in monotherapy, but not yet in combination w/ etesevimab.
In Oct 2020, @gatesfoundation signed a contract w/ Lilly & Fujifilm to manufacture more bamlanivimab. Could it now also include etesevimab?
Concern now is that bamlanivimab is quite accessible in monotherapy, but not yet in combination w/ etesevimab.
In Oct 2020, @gatesfoundation signed a contract w/ Lilly & Fujifilm to manufacture more bamlanivimab. Could it now also include etesevimab?
https://twitter.com/julienpotet/status/1314492596543197185
4/
In 🇫🇷, emergency use of bamlanivimab monotherapy has raised concerns, particularly within context of variants of concern.
What should happen now? Should bamlanivimab be used in monotherapy or should we wait for companion etesevimab to be available?
In 🇫🇷, emergency use of bamlanivimab monotherapy has raised concerns, particularly within context of variants of concern.
What should happen now? Should bamlanivimab be used in monotherapy or should we wait for companion etesevimab to be available?
https://twitter.com/MathieuMolimard/status/1365367391597842434
5/
It is now crucial that @Lillypad discloses its plan to make the cocktail accessible around the world, including in LMICs. The company has had a relatively progressive access policy compared to Regeneron so far, hopefully it'll continue to be the case.
It is now crucial that @Lillypad discloses its plan to make the cocktail accessible around the world, including in LMICs. The company has had a relatively progressive access policy compared to Regeneron so far, hopefully it'll continue to be the case.
https://twitter.com/julienpotet/status/1321466915957710848
6/
Lastly let's continue to seek the holy grail of anti-SARS2 mAbs, e.g. a low-cost, low-dose cocktail for subcutaneous use.
Groups like @IAVI and CoVIC have been working with that target in mind. Fingers crossed.
Lastly let's continue to seek the holy grail of anti-SARS2 mAbs, e.g. a low-cost, low-dose cocktail for subcutaneous use.
Groups like @IAVI and CoVIC have been working with that target in mind. Fingers crossed.
https://twitter.com/julienpotet/status/1270380654430208000
• • •
Missing some Tweet in this thread? You can try to
force a refresh
